share_log

Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel

Benzinga ·  Jan 2 22:16

-If approved, deramiocel would be first approved therapy for Duchenne muscular dystrophy cardiomyopathy-

-BLA submission triggers $10 million milestone payment to Capricor from Nippon Shinyaku-

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment